The specialty drug company King Pharmaceuticals is seeking to acquire the specialty pharmaceutical company Alpharma (Bridgewater, NJ) through an unsolicited bid of $33 per share or $1.4 billion in cash. Alpharma has rejected the bid.
Bristol, TN (Aug. 22)-The specialty drug company King Pharmaceuticals is seeking to acquire the specialty pharmaceutical company Alpharma (Bridgewater, NJ) through an unsolicited bid of $33 per share or $1.4 billion in cash. Alpharma has rejected the bid.
In making the move to acquire Alpharma, Brian A. Markison, chairman, president, and CEO of King Pharmaceuticals, said, “The transaction would create a diversified specialty pharmaceutical company with greater commercialization capabilities, an expanded portfolio of pain management products, and a strengthened pipeline, which would include multiple platform technologies.”
Alpharma reported 2007 sales of $722.4 million, a 10% increase from 2006 sales of $653.8 million. Animal-health products accounted for the largest piece of its business: 50.8% of 2007 sales. The company’s recently divested active pharmaceutical ingredient (API) business accounted for 26% of its 2007 sales, and pharmaceuticals represented 23.2%.
Alpharma’s 2007 pharmaceutical revenues were $167.7 million, an increase of 21% over 2006 levels, but the company reported an operating loss in its pharmaceutical division of $61.5 million in 2007. The company’s lead product is “Kadian” (morphine sulfate). Its lead pipeline candidate is “Embeda” (morphine sulfate extended-release with sequestered naltrexone hydrochloride capsules). The company submitted a revised new drug application for Embeda to the US Food and Drug Administration in June 2008. Pending regulatory approval, Alpharma anticipates launching the product in early 2009.
In April 2008, Alpharma divested its API business to the private equity group 3i for $395 million. The business provides third-party manufacturing for a line of fermentation-based APIs and one chemically synthesized API. The sale included manufacturing facilities in Copenhagen, Denmark; Oslo, Norway; Budapest, Hungary; and Taizhou, China.
Deal is stalled
In a letter to Alpharma president and CEO Dean J. Mitchell, Markison said “we are disappointed” that Alpharma rejected the proposal and added that King Pharmaceuticals was willing to discuss all aspects of the proposal, including structures and economics.
In a response to King Pharmaceuticals, Mitchell opened the possibility of considering a higher offer. “We are willing to entertain a proposal from you that we believe more appropriately values the company,” he said.
As of press time, King Pharmaceuticals had not offered a new proposal.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.